Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis

E. R. Dorsey, J. P. Thompson, K. Noyes, A. W. Dick, R. G. Holloway, S. R. Schwid

Research output: Contribution to journalArticle

Abstract

Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).

Original languageEnglish (US)
Pages (from-to)1524-1528
Number of pages5
JournalNeurology
Volume68
Issue number18
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Quality-Adjusted Life Years
Multiple Sclerosis
Progressive Multifocal Leukoencephalopathy
Insurance Benefits
Recurrence
Health
Natalizumab
Therapeutics
Interferon beta-1a

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Dorsey, E. R., Thompson, J. P., Noyes, K., Dick, A. W., Holloway, R. G., & Schwid, S. R. (2007). Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology, 68(18), 1524-1528. https://doi.org/10.1212/01.wnl.0000260699.09720.ad

Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. / Dorsey, E. R.; Thompson, J. P.; Noyes, K.; Dick, A. W.; Holloway, R. G.; Schwid, S. R.

In: Neurology, Vol. 68, No. 18, 05.2007, p. 1524-1528.

Research output: Contribution to journalArticle

Dorsey, ER, Thompson, JP, Noyes, K, Dick, AW, Holloway, RG & Schwid, SR 2007, 'Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis', Neurology, vol. 68, no. 18, pp. 1524-1528. https://doi.org/10.1212/01.wnl.0000260699.09720.ad
Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology. 2007 May;68(18):1524-1528. https://doi.org/10.1212/01.wnl.0000260699.09720.ad
Dorsey, E. R. ; Thompson, J. P. ; Noyes, K. ; Dick, A. W. ; Holloway, R. G. ; Schwid, S. R. / Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. In: Neurology. 2007 ; Vol. 68, No. 18. pp. 1524-1528.
@article{1fbf7956f82241d28387237d756af63f,
title = "Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis",
abstract = "Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).",
author = "Dorsey, {E. R.} and Thompson, {J. P.} and K. Noyes and Dick, {A. W.} and Holloway, {R. G.} and Schwid, {S. R.}",
year = "2007",
month = "5",
doi = "10.1212/01.wnl.0000260699.09720.ad",
language = "English (US)",
volume = "68",
pages = "1524--1528",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis

AU - Dorsey, E. R.

AU - Thompson, J. P.

AU - Noyes, K.

AU - Dick, A. W.

AU - Holloway, R. G.

AU - Schwid, S. R.

PY - 2007/5

Y1 - 2007/5

N2 - Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).

AB - Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).

UR - http://www.scopus.com/inward/record.url?scp=34247614081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247614081&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000260699.09720.ad

DO - 10.1212/01.wnl.0000260699.09720.ad

M3 - Article

VL - 68

SP - 1524

EP - 1528

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 18

ER -